Akari Therapeutics Plc (AKTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Akari Therapeutics reported revenue of $0. Net income was -$17.3M. Operating activities generated -$10.6M of cash. At fiscal year end, Akari Therapeutics held $47.9M in total assets against $19.6M in total liabilities, including $0 of cash and equivalents.
Open the full interactive Akari Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Akari Therapeutics Key Stats
| Share Price | $7.90 |
|---|---|
| Market Cap | $14.2M |
| 52-Week Range | $3.06 – $39.20 |
| Shares Outstanding | 143.32 billion (basic, 2026 Q2) |
Akari Therapeutics Income Statement
| FY 2014 | FY 2015 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$10.2M | -$30.6M | -$16.8M | -$21.6M | -$17.3M |
| Pre-Tax Income | -$9.6M | -$45.3M | -$10,008 | -$19.8M | -$18.3M |
| Income Tax | — | $0 | $0 | $0 | -$1.0M |
| Net Income | -$9.6M | -$45.3M | -$10.0M | -$19.8M | -$17.3M |
| Diluted EPS | -$1440.00 | -$40.00 | — | — | — |
Akari Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$6.4M | -$5.3M | -$14.5M | -$4.8M |
| Diluted EPS | — | -$0.00 | — | — |
Akari Therapeutics Balance Sheet
| FY 2014 | FY 2015 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $6.2M | $68.9M | $3.8M | $2.6M | $0 |
| Current Assets | $6.4M | $69.7M | $4.3M | $3.0M | $5.5M |
| Total Assets | $6.5M | $69.9M | $4.4M | $50.6M | $47.9M |
| Current Liabilities | $1.4M | $21.1M | — | $19.9M | $12.4M |
| Total Long-Term Debt | — | — | — | $700,000 | $673,000 |
| Total Liabilities | $1.6M | $21.2M | $4.6M | $28.3M | $19.6M |
| Shareholders' Equity | $4.9M | $48.7M | -$229,000 | $22.2M | $28.3M |
Akari Therapeutics Cash Flow Statement
| FY 2014 | FY 2015 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$9.5M | -$5.0M | -$16.4M | -$12.6M | -$10.6M |
| Cash From Investing | -$199,000 | $1.4M | — | $382,000 | — |
| Cash From Financing | $8.2M | $69.0M | $7.0M | $11.0M | $13.2M |
| Free Cash Flow | -$9.5M | -$5.0M | — | — | — |
Figures from Akari Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Akari Therapeutics financials page for every line item.
Akari Therapeutics Company Profile
| Ticker | AKTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Tampa, Florida |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001541157 |
Frequently Asked Questions
What was Akari Therapeutics' revenue in fiscal 2025?
Akari Therapeutics (AKTX) reported revenue of $0 for fiscal 2025.
What is Akari Therapeutics' annual revenue history?
Akari Therapeutics' annual revenue by fiscal year: 2014: $0; 2015: $0; 2023: $0; 2024: $0; 2025: $0.
What was Akari Therapeutics' net income in fiscal 2025?
Akari Therapeutics reported net income of -$17.3M for fiscal 2025.
What was Akari Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Akari Therapeutics reported revenue of $0.
How much debt does Akari Therapeutics have?
Akari Therapeutics reported $673,000 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Akari Therapeutics are outstanding?
Akari Therapeutics reported a weighted average of 143.32 billion basic shares outstanding in 2026 Q2.
What is Akari Therapeutics' market cap?
Based on its latest closing price, Akari Therapeutics (AKTX) has a market capitalization of about $14.2M.
When does Akari Therapeutics' fiscal year end?
Akari Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Akari Therapeutics headquartered?
Akari Therapeutics lists its business address in Tampa, Florida in its SEC filings.